The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results from a phase II study to evaluate the efficacy and safety of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC).
 
Sujun Han
No Relationships to Disclose
 
Yong Zhang
No Relationships to Disclose
 
Xiongjun Ye
No Relationships to Disclose
 
Hongzhe Shi
No Relationships to Disclose
 
Bolin Jia
No Relationships to Disclose
 
Feiya Yang
No Relationships to Disclose
 
Xingang Bi
No Relationships to Disclose
 
Xin Wang
No Relationships to Disclose
 
Wasilijiang Wahafu
No Relationships to Disclose
 
Hongsong Bai
No Relationships to Disclose
 
Linjun Hu
No Relationships to Disclose
 
Nianzeng Xing
No Relationships to Disclose